Takeda continues global R&D reboot with a new joint venture with PRA
Christophe Weber, president and chief executive officer of Takeda Pharmaceutical Co., speaks during the 18th Nikkei Global Management Forum in Tokyo, Japan (CREDIT: Tomohiro Ohsumi/Bloomberg via Getty Images)
Christophe Weber has unleashed some tidal forces in restructuring Takeda’s 236-year-old business. And they’re taking another big step in the process by setting up an R&D joint venture with the big CRO PRA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.